A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

NCT03338881 | Withdrawn Phase 1 FDA Drug

• 3 other identifiers: C34010U1111-1203-69402017-003383-12
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of \[14C\]-TAK-659 solution containing 60 to 80 micro curie (Ci) of total radioactivity in participants with advanced solid tumors and/or lymphomas.

Conditions

Advanced Solid Neoplasms; Lymphoma Neoplasms

Keywords

Drug therapy

Outcome Measures

Primary Outcomes (12)

• Cmax: Maximum Observed Plasma Concentration for TAK-659

  Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

• Cmax: Maximum Observed Plasma and Whole Blood Radioactivity for [14C]-TAK-659

  Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

• Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-659

  Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

• Tmax: Time to Reach the Maximum Plasma and Whole Blood Radioactivity for [14C]-TAK-659

  Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

• AUClast: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration for TAK-659

  Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

• AUClast: Area Under the Plasma and Whole Blood Radioactivity-time Curve from Time 0 to the Time of the Last Quantifiable Radioactivity for [14C]-TAK-659

  Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

• Ae urine,14C: Cumulative Amount of Radioactivity Excreted in Urine for [14C]-TAK-659

  Baseline up to 14 days

• Ae feces, 14C: Cumulative Amount of Radioactivity Excreted in Feces for [14C]-TAK-659

  Baseline up to 14 days

• Ae total: Total Cumulative Amount of Radioactivity Excreted in Urine and Feces for [14C]-TAK-659

  Baseline up to 14 days

• Ae urine: Cumulative Amount of TAK-659 Excreted in Urine

  Baseline up to 14 days

• Percentage of Dose Excreted in Urine for TAK-659

  Baseline up to 14 days

• Renal Clearance (CLR) of TAK-659

  Baseline up to 14 days

Secondary Outcomes (9)

• Percentage of TAK-659 Metabolites in Plasma

  Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose

• Percentage of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

  Baseline up to 28 days after the last dose of study drug (Week 58)

• Percentage of Participants with Grade 3 or Higher Adverse Events (AEs)

  Baseline up to 28 days after the last dose of study drug (Week 58)

• Percentage of Participants with Drug Related AEs

  Baseline up to 28 days after the last dose of study drug (Week 58)

• Percentage of Participants with Drug Related Grade 3 or Higher AEs

  Baseline up to 28 days after the last dose of study drug (Week 58)

Study Arms (1)

[14C]-TAK-659 100 mg

EXPERIMENTAL

\[14C\]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.

Drug: [14C]-TAK-659; Drug: TAK-659

Interventions

[14C]-TAK-659 DRUG

\[14C\]-TAK-659 solution.

[14C]-TAK-659 100 mg

TAK-659 DRUG

TAK-659 tablets.

[14C]-TAK-659 100 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must have histologically or cytologically confirmed metastatic and/or advanced solid tumors and/or lymphomas for which standard curative or life-prolonging treatment does not exist or is no longer effective or tolerable.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
• Life expectancy of at least 3 months.
• Suitable venous access for the study-required blood sampling (that is, PK).
• Recovered (that is, grade less than or equal to \[\<=\] 1 toxicity) from the reversible effects of prior anticancer therapy (with the exception of alopecia and Grade 1 neuropathy).
• Must have adequate organ function, including the following:
• Adequate bone marrow reserve: absolute neutrophil count (ANC) greater than or equal to (\>=) 1000 per microliter (/mcL); platelet count \>=75,000/mcL (\>=50,000/mcL for participants with bone marrow involvement); and hemoglobin \>=8 gram per deciliter (g/dL) (red blood cell \[RBC\] and platelet transfusion allowed \>=14 days before assessment).
• Hepatic: total bilirubin \<=1.5 times the upper limit of the normal range (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=2.5\*ULN.
• Renal: creatinine clearance \>=60 milliliter per minute (mL/min) either as estimated by the Cockcroft-Gault equation or based on urine collection

You may not qualify if:

• Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases, as indicated by positive cytology from lumbar puncture or computed tomography (CT) scan/magnetic resonance imaging (MRI).
• Known human immunodeficiency virus (HIV) positivity or HIV-related malignancy.
• Systemic anticancer treatment (including investigational agents) or radiotherapy within 3 weeks before the first dose of study treatment \<=5 times the half-life for large molecule agents or \<=4 weeks with evidence of progressive disease if 5 times the half-life is greater than (\>) 4 weeks.
• Use or consumption of any of the following substances:
• Medications or supplements that are known to be inhibitors of P-glycoprotein (P-gp) and/or strong reversible inhibitors of cytochrome P450 (CYP) 3A within 5 times the inhibitor half-life (if a reasonable half-life estimate is known), or within 7 days (if a reasonable half-life estimate is unknown), before the first dose of study drugs
• Medications or supplements that are known to be strong CYP3A mechanism-based inhibitors or strong CYP3A inducers and/or P-gp inducers within 7 days or within 5 times the inhibitor or inducer half-life (whichever is longer) before the first dose of study drugs. In general, the use of these agents is not permitted during the study except when an AE must be managed during interruption of study drug dosing.
• Food or beverages containing grapefruit within 5 days before the first dose of study drugs. Note that food and beverages containing grapefruit are not permitted during the study.
• Ongoing nausea or vomiting that is Grade 2 or worse in intensity.
• Systemic infection requiring intravenous (IV) antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
• Active secondary malignancy that requires treatment. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection and are considered disease-free at the time of study entry.
• Irregular defecation patterns and/or history of urinary and/or fecal incontinence.

Sponsors & Collaborators

• Calithera Biosciences, Inc: lead

MeSH Terms

Interventions

TAK-659

Study Officials

• Medical Director

  Millennium Pharmaceuticals, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 8, 2017
• First Posted: November 9, 2017
• Study Start: May 10, 2018
• Primary Completion: May 1, 2019
• Study Completion: May 1, 2019
• Last Updated: February 8, 2023

Record last verified: 2023-02